ReviewACS infectious diseases2022
Two Years into the COVID-19 Pandemic: Lessons Learned.
Review in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Effectiveness of SARS-CoV-2 testing strategies in reducing COVID-19 cases, hospitalisations, and deaths.The Cochrane database of systematic reviews · 2025Pooled it
- Mother-to-child transmission of SARS-CoV-2 infection in high-income countries: a systematic review and meta-analysis of prospective observational studies.Scientific reports · 2023Pooled it
- The Reverse Risk Register Approach to Understanding Systemic Factors in Risk Analysis and Management Case Studies.Risk analysis : an official publication of the Society for Risk Analysis · 2026Article
- International multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity.Science advances · 2026Article
- Rapid On-Site Detection ofPlants (Basel, Switzerland) · 2026Article
- SARS-CoV-2 Orf3a protein interaction mapping using unnatural amino acid incorporation.Protein engineering, design & selection : PEDS · 2026Article
- Evaluation of the Quantitative and Structural Antimicrobial Activity of Thymol, Terpinen-4-ol, Citral, and E-2-Dodecenal, Antibiotic Molecules Derived from Essential Oils.Antibiotics (Basel, Switzerland) · 2025Article
- Mortality and associated factors among hospitalised COVID-19 patients in Lira regional referral hospital, a cross-sectional study.BMJ open · 2025Article
- Predictive Ability of Previous Pain and Disease Conditions on the Presentation of Post-COVID Pain in a Danish Cohort of Adult COVID-19 Survivors.European journal of pain (London, England) · 2025Article
- A preliminary validation of the public's emergency preparedness questionnaire for major emerging infectious diseases.BMC public health · 2025Article
- Implementing SARS-CoV-2 Testing during a Large-Scale Sporting Event in Africa: Lessons Learned from the Africa Football Cup of Nations Tournament in Cameroon.The American journal of tropical medicine and hygiene · 2025Article
- Pain Complaints and Intubation Risk in COVID-19 Patients: A Retrospective Cross-Sectional Analysis.Cureus · 2025Article
- Challenges of Ventilator Procurement and Distribution in the ICU During the COVID-19 Pandemic: A Scoping Review.Critical care explorations · 2025Article
- Article
- Effectiveness of SARS-CoV-2 testing strategies.The Cochrane database of systematic reviews · 2025Article
- Role of toll-like receptors in post-COVID-19 associated neurodegenerative disorders?Frontiers in medicine · 2025Review
- Multisectoral coordination in public health: insights from the 8th EMPHNET regional conference.Frontiers in public health · 2025Article
- COVID-19 as cause of death: a bridge coding study.GMS infectious diseases · 2025Article
- Article
- Rare host variants in ciliary expressed genes contribute to COVID-19 severity in Bulgarian patients.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan, China, causing a respiratory disease called coronavirus disease 2019 (COVID-19), which has massively impacted global public health and caused widespread disruption to daily life. The crisis caused by COVID-19 has mobilized scientists and public health authorities across the world to rapidly improve our knowledge about this devastating disease, shedding light on its management and control, and spawned the development of new countermeasures. Here we provide an overview of the state of the art of knowledge gained in the last 2 years about the virus and COVID-19, including its origin and natural reservoir hosts, viral etiology, epidemiology, modes of transmission, clinical manifestations, pathophysiology, diagnosis, treatment, prevention, emerging variants, and vaccines, highlighting important differences from previously known highly pathogenic coronaviruses. We also discuss selected key discoveries from each topic and underline the gaps of knowledge for future investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.